Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 65-year-old man is evaluated in the intensive care unit. He was admitted 12 days ago for status epilepticus and subsequently developed ventilator-associated pneumonia. He was intubated and received continuous enteral nutrition via a nasogastric tube. His seizures have been well controlled on enteral phenytoin suspension, requiring a high dose of 400 mg every 8 hours to maintain a therapeutic total serum trough level of 16 mcg/mL. His pneumonia is being treated with intravenous meropenem.

Today, the patient's respiratory status has significantly improved, and he is extubated. The continuous enteral feeds are discontinued, and he successfully passes a swallowing evaluation. He is advanced to a standard oral diet and is scheduled to transition to oral phenytoin capsules. His serum albumin is 3.5 g/dL. Renal and hepatic functions are within normal limits.

Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Empirically reduce the phenytoin dose and closely monitor serum trough levelsAnswer
  2. B
    Continue the same total daily dose of phenytoin and monitor for clinical signs of nystagmus or ataxia
  3. C
    Measure a serum free phenytoin level to account for the transition from suspension to capsules
  4. D
    Substitute meropenem with cefepime to prevent accelerated hepatic clearance of the antiepileptic
  5. E
    Maintain the same total daily dose but check a trough level 1 hour after the first oral capsule dose

Answer

Empirically reduce the phenytoin dose and closely monitor serum trough levels
The correct answer is to empirically reduce the phenytoin dose and closely monitor serum trough levels. Continuous enteral nutrition formulas physically bind to phenytoin in the gastrointestinal tract, significantly impairing its absorption. To achieve therapeutic serum levels while on continuous feeds, patients often require exceptionally high compensatory doses (e.g., 1200 mg/day, as seen in this patient). When enteral feeding is discontinued and the patient transitions to a standard oral diet, this binding interaction is eliminated, leading to a sudden and massive increase in phenytoin bioavailability. Because phenytoin exhibits saturable, Michaelis-Menten (zero-order) pharmacokinetics at therapeutic concentrations, continuing the high compensatory dose will rapidly result in severe toxicity. Therefore, the dose must be empirically reduced, followed by vigilant trough level monitoring.

Step-by-Step Solution

1
Identify the patient's current clinical transition and relevant medication.
The patient is taking phenytoin and is transitioning from continuous enteral nutrition to a standard oral diet.
Recognizing changes in diet or feeding routes is critical for highly bound or poorly absorbed medications.
2
Evaluate the current medication dosage in the context of the feeding route.
The patient requires a massive dose of 1200 mg/day (400 mg every 8 hours) to maintain therapeutic levels, which is far above the standard maintenance dose.
Enteral nutrition formulas physically bind to phenytoin suspension in the gastrointestinal tract, significantly impairing its absorption and necessitating high compensatory doses.
3
Predict the pharmacokinetic consequence of discontinuing the enteral feeds.
Removing the enteral feeds eliminates the binding interaction, leading to a sudden and massive increase in the amount of bioavailable phenytoin absorbed from the gastrointestinal tract.
Phenytoin exhibits saturable, Michaelis-Menten (zero-order) pharmacokinetics at therapeutic concentrations, meaning any increase in absorption will disproportionately elevate serum levels.
4
Determine the most appropriate proactive clinical intervention.
Empirically reduce the phenytoin dose to a standard maintenance level and closely monitor serum trough levels.
Maintaining the compensatory high dose without enteral feeds will rapidly lead to severe neurological toxicity.

Key Concept

Pharmacokinetic interaction between continuous enteral nutrition and phenytoin absorption
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic